Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration

16 Jul 2019

Abstract excerpt

PURPOSE: Geographic atrophy (GA), a late stage of age-related macular degeneration (AMD), is a major cause of blindness. Even while central visual acuity remains relatively well preserved, GA often causes considerable compromise of visual function and quality of life. No treatment currently exists. We evaluated the safety and efficacy of pegcetacoplan, a complement C3 inhibitor, for treatment of GA. DESIGN:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Complement system in diseases
Share to Retinal Development and Disorders
Share to Retinal Diseases and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31474439
DOI: 10.1016/j.ophtha.2019.07.011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular DegenerationPMID 31474439Read ↗

COMPLEMENT INHIBITION FOR GEOGRAPHIC ATROPHYSemantic proximity Read ↗

Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study.Semantic proximity Read ↗

Local Complement Inhibition for Geographic Atrophy in Age-Related Macular Degeneration: Prospects, Challenges, and Unanswered QuestionsSemantic proximity Read ↗

Treating patients with geographic atrophy: are we there yet?Semantic proximity Read ↗

Real-World Outcomes with Complement Inhibitors for Geographic Atrophy: A Comparative Study of Pegacetacoplan versus Avacincaptad PegolSemantic proximity Read ↗

Complement cascade inhibition in geographic atrophy: a review.Semantic proximity Read ↗

The roadmap to geographic atrophy treatment: A journey of trials and promiseSemantic proximity Read ↗

Geographic atrophy: where we are now and where we are goingSemantic proximity Read ↗

Complement system modulation in age-related macular degeneration: navigating failures, building future successesSemantic proximity Read ↗

Informing Endpoints for Clinical Trials of Geographic AtrophySemantic proximity Read ↗

Therapeutic Approaches with Intravitreal Injections in Geographic Atrophy Secondary to Age-Related Macular Degeneration: Current Drugs and Potential MoleculesSemantic proximity Read ↗

Incidence and progression of geographic atrophy: observations from a population-based cohort.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.